Metachromatic Leukodystrophy (MLD)
Oncology·MeSH: Leukodystrophy, Metachromatic
Prevalence
0.5 / 100K
4 drugs in development·2 companies·3 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| libmeldy | Orchard Therapeutics plc (ORTX) |
Phase 2(2)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| hgt-1110 | SHIRE PLC (SHPGF) |
Compare drugs
Frequently asked questions
How many drugs are in development for Metachromatic Leukodystrophy (MLD)?
BioSniper tracks 4 drugs in development for Metachromatic Leukodystrophy (MLD) across 2 companies.
How many clinical trials target Metachromatic Leukodystrophy (MLD)?
There are 3 clinical trials targeting Metachromatic Leukodystrophy (MLD) tracked by BioSniper.
What is the prevalence of Metachromatic Leukodystrophy (MLD)?
The estimated prevalence of Metachromatic Leukodystrophy (MLD) is approximately 0.5 per 100,000 population.
Deep-dive into Metachromatic Leukodystrophy (MLD)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis